Senate Leaders Warn Defense Department About Procuring Generic Drugs Overseas

Senate leaders are urging the Department of Defense to prioritize U.S.-made generic drugs, warning that reliance on foreign manufacturers, particularly from China, poses an "existential risk" to the military. Senators Rick Scott and Kirsten Gillibrand sent a letter requesting details on foreign drug purchases and inventory resilience, citing concerns over unstable global trade and previous FDA exemptions for foreign factories with safety violations. This initiative, building on prior investigations into generic drug oversight, aims to strengthen the vulnerable drug supply chain for servicemembers and address national security, economic, and patient safety concerns. The senators also introduced the Clear Labels Act to increase transparency on drug origins.